

"Express Mail" mailing label number EL 856 154 781US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Commissioner for Patents, Box Patent Application, Washington, D.C. 20231 on Oct. 3, 2001

By: Nancy Ramos

Printed: Nancy Ramos



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hillman et al.

Title: HUMAN TUMOR SUPPRESSOR POLYPEPTIDES

Serial No.: To Be Assigned

Filing Date: Herewith

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

Box Patent Application  
Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure.

Applicants respectfully submit under 37 C.F.R. 1.98(3)(d) that copies of the references are not included herein as copies were previously cited by or submitted to the Office in prior application Serial No. 09/205,749, filed December 4, 1998, which a divisional of U.S. application Serial No. 08/822,262, filed March 20, 1997, now U.S. Patent No. 5,849,899, from which we are claiming priority under 35 U.S.C. 120.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI

report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. **09-0108**. **A duplicate copy of this communication is enclosed.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-855-0555.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: October 3, 2001

Barrie D. Greene

Barrie D. Greene

Reg. No. 46,740

Direct Dial Telephone: (650) 621-7576

3160 Porter Drive  
Palo Alto, California 94304  
Phone: (650) 855-0555  
Fax: (650) 845-4166

U.S. Department of Commerce, Patent and Trademark Office	Atty Docket No.	Serial No.
	PF-0249-2 CON	To Be Assigned
LIST OF REFERENCES CITED BY APPLICANTS	Applicants	
(Use several sheets if necessary)	Hillman and Shah	
	Filing Date	Group
	Herewith	To Be Assigned

## U.S. Patent Documents

*Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## Foreign Patent Documents

							Translation
	Document	Date	Country	Class	Subclass	Yes	No

## OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

1	Knudson, A., "Antioncogenes and human cancer," <u>Proc. Natl. Acad. Sci. USA</u> , 90:10914-10921 (1993)
2	Antelman, D., et al., "Inhibition of tumor cell proliferation <i>in vitro</i> and <i>in vivo</i> by exogenous p110 <sup>RB</sup> , the retinoblastoma tumor suppressor protein," <u>Oncogene</u> , 10:697-704 (1995)
3	Hamada, K., et al., "Adenovirus-mediated Transfer of a Wild-Type p53 Gene and Induction of Apoptosis in Cervical Cancer," <u>Cancer Research</u> , 56:3047-3054 (1996)
4	Todd, R., et al., "Deleted in oral cancer-1 (doc-1), a novel oral tumor suppressor gene," <u>The FASEB Journal</u> , 9:1362-1370 (1995) (GI 606837)
5	Gordon, H. et al., "Tumor Necrosis Factor Induces Genes Involved in Inflammation, Cellular and Tissue Repair, and Metabolism in Murine Fibroblasts," <u>The Journal of Immunology</u> , 148(12):4021-4027 (1992) (GI 202234)
6	Chang, F., et al., "Implications of the p53 Tumor-Suppressor Gene in Clinical Oncology," <u>Journal of Clinical Oncology</u> , 13(4):1009-1022 (1995)
7	Jacobson, D., et al., "Molecular genetic tumor markers in the early diagnosis and screening of non-small-cell lung cancer," <u>Annals of Oncology</u> , 6(3):S3-S8 (1995)
8	Vokes, E., et al., "Head and Neck Cancer," <u>The New England Journal of Medicine</u> , 328(3):184-194
9	Silverman, S., et al., "Epidemiologic and demographic update in oral cancer: California and national data-1973 to 1985," <u>JADA</u> , 120:495-499 (1990)
10	Wong, D.T. (Direct Submission), GenBank Sequence Database (Accession U10249), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894, (GI 606837).
11	Wong, D.T. (Direct Submission), GenBank Sequence Database (Accession U10249), National Center for Biotechnology Information, National Library of Medicine, Bethesda, Maryland, 20894, (GI 606836).

Examiner

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with your communication to applicant.

Examiner

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation of not in conformance and not considered. Include copy of this form with your communication to applicant.